FOLFOX Chemotherapy Combined With Fruquintinib and Serplulimab as First-Line Conversion Therapy for Initially Unresectable pMMR/MSS Colorectal Cancer

StatusNot Yet Recruiting
PhasePhase 4
SponsorYe Xu
Started

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Track this trial
View on ClinicalTrials.gov ↗

Record History

  1. Study First Submitted
Ye Xu
1 trial monitored
See all monitored trials
Colorectal Cancer
3,420 trials monitored
See 164 trials at risk
To evaluate the efficacy and safety of immune checkpoint inhibitor-based combination therapy with targeted therapy and chemotherapy in patients with locally advanced unresectable or metastatic colorectal cancer.
Trial Details
NCT Number NCT07446465
Lead Sponsor Ye Xu
Conditions
(from sponsor)		 Colorectal Cancer (Locally Advanced or Metastatic), Colorectal Cancer Microsatellite Stable (MSS)
Related terms Colorectal Neoplasms, Neoplasm Metastasis
Enrollment 42 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov